Rigel Pharmaceuticals Welcomes Michael P. Miller to Board
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), based in South San Francisco, has made a significant move by appointing Michael P. Miller to its Board of Directors. With over four decades of experience in the biotechnology and pharmaceutical sectors, Mr. Miller is poised to bring invaluable expertise to the company.
Bringing Expertise to the Board
Raul Rodriguez, the President and CEO of Rigel, expressed excitement about this new addition to the board. Rodriguez highlighted that Mike Miller's outstanding track record in commercial success makes him an ideal candidate to guide the company through its ongoing strategic initiatives. These include expanding their pharmaceutical portfolio and exploring new opportunities for in-licensing, areas where Miller holds vast knowledge.
A Wealth of Experience
Before joining the Rigel Board, Mr. Miller was a key figure at Puma Biotechnology and BioXcel Therapeutics. He served Jazz Pharmaceuticals as the Executive Vice President of U.S. Commercial from April 2014 until his retirement in September 2020. His extensive background also includes roles at Vivus and Genentech, where he led initiatives that shaped the landscape of oncology treatments. His impressive resume includes key positions in various well-regarded companies, proving his versatility and leadership capabilities in the industry.
Vision for Rigel's Future
In his statement, Mr. Miller highlighted Rigel’s impressive evolution into a commercially successful entity that supports a promising line of developmental therapies. He expressed eagerness about joining Rigel as a Director, aiming to contribute to the company's mission of enhancing treatment options for patients battling hematologic disorders and cancers.
About Rigel Pharmaceuticals
Founded in 1996, Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a biotechnology firm dedicated to discovering and developing innovative therapies aimed at significantly improving patient lives, particularly for those dealing with hematologic disorders and cancer. The company promises a bright future in biotechnology with its commitment to harnessing advanced technologies and deep industry knowledge.
Contacting Rigel Pharmaceuticals
For investor inquiries, Rigel can be reached at 650.624.1232. Their dedicated investor relations are always ready to provide updates and engage with stakeholders. Similarly, media inquiries can be directed to David Rosen at Argot Partners by calling 646.461.6387. Both avenues are open for ongoing communication about Rigel’s developments and market strategies.
Frequently Asked Questions
What position was Michael P. Miller appointed to at Rigel Pharmaceuticals?
Michael P. Miller has been appointed to the Board of Directors at Rigel Pharmaceuticals.
How will Miller's experience benefit Rigel?
His extensive experience in biotechnology and commercial roles will provide valuable insights as Rigel works on its strategic initiatives.
What is Rigel Pharmaceuticals’ primary focus?
Rigel is focused on developing therapies for hematologic disorders and cancer.
When was Rigel Pharmaceuticals founded?
Rigel Pharmaceuticals was founded in 1996 and has since been committed to improving patient care through innovative solutions.
What is Rigel's stock ticker?
Rigel Pharmaceuticals is traded under the ticker symbol RIGL on NASDAQ.
